$3M Gene Therapy—With a Catch - Top-Institutions - MDSpire

$3M Gene Therapy—With a Catch

Medicaid is testing a pay-for-performance deal that makes drugmakers refund millions if new sickle cell gene therapies fail.

  • By

  • Phil Galewitz

  • January 21, 2026

  • 8 min

Share

Top Institutions in Internal Medicine

Brief introduction explaining scope and methodology.

  • #1

    National Institutes of Health (NIH) - National Heart, Lung, and Blood Institute (NHLBI)
    National Institutes of Health (NIH) - National Heart, Lung, and Blood Institute (NHLBI)

    Bethesda, MD

    Key Differentiators

    • Hematology
    • Gene Therapy
    • Clinical Research

  • #2

    University of California, Los Angeles (UCLA) - Center for Sickle Cell Disease
    University of California, Los Angeles (UCLA) - Center for Sickle Cell Disease

    Los Angeles, CA

    Key Differentiators

    • Hematology
    • Gene Therapy
    • Pediatric Hematology

  • #3

    Boston Children's Hospital - Center for Sickle Cell Disease
    Boston Children's Hospital - Center for Sickle Cell Disease

    Boston, MA

    Key Differentiators

    • Pediatric Hematology
    • Gene Therapy
    • Stem Cell Transplantation

  • #4

    University of Pennsylvania - Abramson Cancer Center
    University of Pennsylvania - Abramson Cancer Center

    Philadelphia, PA

    Key Differentiators

    • Hematology
    • Gene Therapy
    • Cellular Therapy

  • #5

    St. Jude Children's Research Hospital
    St. Jude Children's Research Hospital

    Memphis, TN

    Key Differentiators

    • Pediatric Hematology
    • Gene Therapy
    • Genetic Disorders

Original Source(s)

$3M Gene Therapy—With a Catch

  • by Phil Galewitz

  • January 21, 2026

Related Content

Why FDA Said No to a Melanoma Drug

Questions over trial design and political pressure shadowed the rejection of Replimune’s RP1 treatment.

CT Use May Add to Future Cancer Burden

Researchers projected approximately 103,000 future cancers associated with computed tomography examinations performed in the US in 2023.

Biologics Commonly Used in Cutaneous Crohn's Disease

Retrospective multicenter cohort highlights genital-predominant presentation patterns and frequent combination therapy use in cutaneous Crohn's disease.